All In Biotech

Drug Trial Radar · NCT00566982

A Clinical Study to Evaluate the Safety of Ospemifene

Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo

Last checked: Nov 20, 2026Latest source record: May 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 426 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

426

Actual

Start

Oct 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
Collaborators
Hormos Medical; QuatRx Pharmaceuticals
First posted
Dec 4, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus.

Conditions

  • Atrophy
  • Vaginal Diseases

Interventions

  • Ospemifene 60 mgDrug

    60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.

  • PlaceboDrug

    Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal SmearTime frame: 12 weeks
  2. Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of Vaginal SmearTime frame: 12 weeks
  3. Mean Change From Baseline in Vaginal pHTime frame: 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.